RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..1 of 1 - per page
Order by
Nanomaterials coupled to human UDP-glucuronosyltransferase genes: enhanced tissue and cellular delivery of therapeutic levels of DNA (10-04)
Composition of Matter - Cancer Therapy More
Displaying 1..1 of 1 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
FDA Approval for Xgeva (denosumab): Novel Therapies to Drive the Bone Metastases Therapy Market
Dec 2010 - 5 pages - $500
Supportive Care in Oncology Market Forecast
Nov 2009 - $15,200
US Oncology, Inc. - SWOT Analysis
Nov 2010 - 26 pages - $125
Bone Cancer Global Clinical Trials Review, Q4, 2010
Oct 2010 - 43 pages - $1,000
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
Company Financials: Cougar Biotechnology, Inc.
Jan 2010 - $75
Bone Cancer Global Clinical Trials Review, H2, 2011
Aug 2011 - 109 pages - $1,000
Molecular Targeted Cancer Therapies Market Forecast
Aug 2009 - $15,200
Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents
Mar 2008 - 100 pages - $3,800
Cancer Targeted Therapies and Immunotherapies Market Forecast
Aug 2010 - $15,200
More Related Market Research Reports >>>

Your selection

Industry sector
Biotechnology del
Nanotechnology del
Therapeutic target
Oncology del
Bone cancer del

Browse By

Therapeutic target
Chondrosarcoma
Ewings Sarcoma
Osteosarcoma
Spindle sarcoma
Development phase
Early Stage
Preclinical
Phase I
Phase I/II
Phase II
Phase III
Phase III/IV
Preregistration
Registered

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us